title: A specific cell-penetrating peptide induces apoptosis in SKOV3 cells by down-regulation of Bcl-2.
abstract: Peptides are emerging as pharmaceutical agents in cancer therapy. The peptide, TLSGAFELSRDK (TLS) is a targeting ligand that can specifically triggers cellular uptake by binding to SKOV3 cells. Cell surface proteins and the C-terminal basic residues of the TLS are required for effective cell penetration, and the uptake process is energy-dependent. It inhibited the proliferation of SKOV3 cells and induced early-stage apoptosis by down-regulation of Bcl-2 expression mediated through a caspase-dependent pathway. The synergistic anti-proliferative effects of the peptide TLS and doxorubicin on SKOV3 cells were further investigated. Taken together, TLS, acting as a combination of a targeted ligand and a therapeutic agent, was a promising candidate for the development of peptide-based therapies in ovarian cancer.
authors.forename: Chuying
authors.initials: C
authors.lastname: Ma
authors.forename: Guangfu
authors.initials: G
authors.lastname: Yin
authors.forename: Fei
authors.initials: F
authors.lastname: You
authors.forename: Yan
authors.initials: Y
authors.lastname: Wei
authors.forename: Zhongbing
authors.initials: Z
authors.lastname: Huang
authors.forename: Xianchun
authors.initials: X
authors.lastname: Chen
authors.forename: Danhong
authors.initials: D
authors.lastname: Yan
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism*; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015536:Down-Regulation; D004317:Doxorubicin / Q000378:metabolism; D004357:Drug Synergism; D004847:Epithelial Cells / Q000187:drug effects*; D006801:Humans; D010455:Peptides / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*
chemical_list: D000970:Antineoplastic Agents; D010455:Peptides; D019253:Proto-Oncogene Proteins c-bcl-2; D004317:Doxorubicin